▶ BPC-157 · SUBTOPIC · SAFETY PROFILE
BPC-157 Safety Profile
For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of BPC-157.
OBSERVED ADVERSE EVENTS IN LITERATURE
The following adverse events have been observed in trials or animal studies of BPC-157. Severity, frequency, and attribution depend on the source publication.
- Limited human safety data
- Animal toxicology shows wide therapeutic window
- Injection-site reactions reported anecdotally
DRUG INTERACTIONS
The following interactions are reported in or theorised from the published mechanism for BPC-157.
- Anticoagulants (theoretical, due to angiogenic activity · unstudied)
CONTRAINDICATIONS REPORTED IN LITERATURE
Contraindications recorded for BPC-157 in the published record:
- Active malignancy (theoretical, due to angiogenic mechanism)
- Pregnancy/lactation (unstudied)
FDA REGULATORY STATUS
Placed on FDA Category 2 of the 503A bulks list (September 2023 update), barring compounding pharmacies from preparing it under section 503A. Not FDA-approved for any human use.
WADA REGULATORY STATUS
Prohibited at all times (in-competition and out-of-competition) under S0 'non-approved substances' since the 2022 Prohibited List.
SAFETY Q+A FROM LITERATURE
▶ Is BPC-157 legal in 2026?
In the US: BPC-157 is on FDA Category 2 of the 503A bulks list (Sept 2023 update), meaning compounding pharmacies cannot prepare it. It is sold as a research-grade chemical reference compound. WADA prohibits it in all sports under S0.
▶ Is BPC-157 FDA-approved?
No. BPC-157 is not FDA-approved for any human indication.
▶ Side effects of BPC-157?
Animal toxicology shows a wide therapeutic window with no documented LD1. Human safety data are limited. Theoretical concerns include unstudied effects in active malignancy (via angiogenesis) and pregnancy.
▶ Why was BPC-157 placed on the FDA bulks list?
The September 2023 503A bulks-list update placed BPC-157 in Category 2, citing insufficient evidence for the FDA to determine that compounding it for routine clinical use is safe and effective. The substance remains available as a research-grade chemical reference compound.
CITED LITERATURE
The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.
- Sikiric P, Sever M, Krezic I, et al.. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology 2024. PMID 38980576. link
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res 2006. PMID 16583442. link
- Staresinic M, Sebecic B, Patrlj L, et al.. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res 2006. PMID 16609979. link
- Matek D, Matek I, Japjec M, et al.. Tendon, Ligament, and Muscle Injury · Cytoprotection Review with BPC 157. Pharmaceuticals (Basel) 2026. PMID 41754849. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19